Aktis Oncology, Inc.
AKTSNasdaq
$24.89
↓ -0.5%Jul 17 close · end-of-day
Price
1Y↑ +11.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Our principal executive offices are located in Boston, Massachusetts.
- CEO
- Matthew Roden
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 76
- Headquarters
- Massachusetts
- Website
- www.aktisoncology.com
Management & directors
- Czibere AkosChief Medical Officer
- Ron-Bigger ShulamitChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
AKTS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$3.2M↑ +123.0%
Diluted EPS-$0.38↓ -98.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
No annual data.
| Line item | Q1 '25 | Q1 '26 |
|---|---|---|
| Revenue | $1.4M | $3.2M |
| Gross profit | — | — |
| Operating income | -$18.1M | -$22.7M |
| Net income | -$15.0M | -$18.3M |
| Diluted EPS | -$18.60 | -$0.38 |
| Operating cash flow | -$17.5M | -$24.2M |
| Free cash flow | -$19.4M | -$26.1M |
| Gross margin | — | — |
| Operating margin | -1253.8% | -703.6% |
| Net margin | -1035.6% | -567.9% |
Company news
May 27, 2026
May 25, 2026
May 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-08 | Czibere Akos· Chief Medical Officer | Sale | 30,829 | $27.95 | $861,735.29 | filing |
| 2026-07-08 | Ron-Bigger Shulamit· Chief Operating Officer | Sale | 30,000 | $27.94 | $838,137.00 | filing |
| 2026-07-08 | Ron-Bigger Shulamit· Chief Operating Officer | Sale | 15,800 | $27.13 | $428,680.86 | filing |
| 2026-07-08 | Czibere Akos· Chief Medical Officer | Sale | 14,800 | $27.13 | $401,484.04 | filing |
| 2026-07-08 | Czibere Akos· Chief Medical Officer | Option exercise | 50,000 | $4.95 | $247,500.00 | filing |
| 2026-07-08 | Ron-Bigger Shulamit· Chief Operating Officer | Option exercise | 50,000 | $3.66 | $183,000.00 | filing |
| 2026-07-08 | Czibere Akos· Chief Medical Officer | Sale | 4,371 | $28.71 | $125,481.79 | filing |
| 2026-07-08 | Ron-Bigger Shulamit· Chief Operating Officer | Sale | 4,200 | $28.75 | $120,739.92 | filing |
| 2026-01-12 | EcoR1 Capital, LLC | Buy | 2,077,779 | $18.00 | $37.4M | filing |
| 2026-01-12 | GADICKE ANSBERT | Buy | 1,112,777 | $18.00 | $20.0M | filing |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P. | Buy | 1,112,777 | $18.00 | $20.0M | filing |
| 2026-01-12 | Kim Helen Susan | Buy | 812,455 | $18.00 | $14.6M | filing |
| 2026-01-12 | Vida Ventures II, LLC | Buy | 812,455 | $18.00 | $14.6M | filing |
| 2026-01-12 | Foley Todd | Buy | 232,870 | $18.00 | $4.2M | filing |
| 2026-01-12 | EcoR1 Capital, LLC | Buy | 144,443 | $18.00 | $2.6M | filing |
| 2026-01-12 | Vida Ventures II, LLC | Buy | 22,545 | $18.00 | $405,810.00 | filing |
| 2026-01-12 | Kim Helen Susan | Buy | 22,545 | $18.00 | $405,810.00 | filing |
| 2026-01-12 | Segal Lloyd Mitchell | C | 19,631 | — | — | filing |
| 2026-01-12 | Vida Ventures II, LLC | C | 134,842 | — | — | filing |
| 2026-01-12 | Foley Todd | C | 597,391 | — | — | filing |
| 2026-01-12 | Foley Todd | C | 2,688,270 | — | — | filing |
| 2026-01-12 | Foley Todd | C | 716,872 | — | — | filing |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P. | C | 1,314,262 | — | — | filing |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P. | C | 5,914,197 | — | — | filing |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P. | C | 1,577,119 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.